Dermatology News

Treatment with intravenous ceftaroline fosamil, with optional conversion to oral medication, was as effective and well-tolerated as comparator therapy in children with acute bacterial skin and skin structure infections, according to recent research.

BOSTON — A single IV dose of Dalvance appears to be comparable to two-dose regimens for the treatment of acute bacterial skin and skin structure infection, and remains so when treating patients with a history of injection drug use, according to data presented at ASM Microbe 2016.

The FDA has expanded the indication for Teflaro, an injectable antibiotic in the cephalosporin class, to treat pediatric patients aged 2 months to 18 years with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, including MRSA.

Incidence of herpes zoster increased more than fourfold within the population of a Minnesota county over approximately 60 years, according to a recently published cohort study.

The FDA has issued a warning to health care professionals to avoid prescribing Nizoral oral tablets to treat skin and nail fungal infections, as it includes a risk for serious liver damage, adrenal gland problems and harmful interactions with other medications.

Papular eruptions and other mucocutaneous findings were linked to confirmatory testing for Zika virus infection, according to study results recently published in JAMA Dermatology.

Researchers found no skin and soft tissue infection or systemic infections after administering more than 130,000 allergen immunotherapy treatments to patients at Massachusetts General Hospital and Brigham and Women’s Hospital, according to a recent study published in The Journal of Allergy and Clinical Immunology.

A recently published literature review suggests approximately 8% of athletes and 13% of collegiate athletes in the United States may be asymptomatically colonized with MRSA.

BALTIMORE — The investigational herpes simplex virus-2 vaccine GEN-003 was well-tolerated and reduced viral shedding and genital lesions up to 1 year after vaccination, according to data presented at the Annual Conference on Vaccine Research.

Focus Diagnostics has recalled its laboratory examination kits for herpes simplex virus 1 and 2 and group A streptococcus infection due to inaccurate test results, according to a press release. The FDA identified the event as a class 1 recall, as use of the devices may result in serious injuries or death.